# Signals Article: Putative Target Q92542 for Hidradenitis Suppurativa
Background
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition characterized by painful nodules and abscesses. Despite its prevalence, the pathogenesis of HS remains poorly understood, and effective treatments are limited. Recent advances in genomic and proteomic data mining have opened new avenues for identifying potential therapeutic targets. One such candidate is the putative target Q92542, identified through a reanalysis of expression-profiling studies.
Data-mining rationale
The identification of Q92542 as a putative target for HS emerged from a cross-referencing effort involving UniProt's reviewed human entries for "hidradenitis suppurativa" and expression-profiling studies in the NCBI GEO database. Although Q92542 has not yet been explored in clinical trials, its presence in multiple datasets suggests a potential role in HS pathophysiology. This target was identified alongside UniProt entries Q9NZ42 and P49768, which were also examined for their relevance to HS.
Why prior analyses may have missed this
Many of the GEO datasets relevant to HS predate the application of modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. Earlier analyses may have lacked the statistical power and rigor provided by these methods, potentially overlooking significant targets like Q92542. By reanalyzing these datasets with limma and applying a Benjamini-Hochberg false discovery rate (FDR) correction, we can more reliably identify differentially-expressed genes that warrant further investigation.
Reasoning for further validation
To substantiate Q92542 as a viable target for HS, several experimental steps are recommended:
1. **Re-analysis of GEO datasets**: Utilize limma with a Benjamini-Hochberg FDR threshold of < 0.05 to identify top differentially-expressed genes.
2. **Validation by qPCR**: Confirm the differential expression of Q92542 in an independent cohort using quantitative PCR, ensuring the reproducibility of findings.
3. **Tissue specificity assessment**: Investigate the expression profile of Q92542 in relevant tissues using resources like GTEx and the Human Protein Atlas to understand its potential role in HS.
4. **Pathway context analysis**: Employ tools such as STRING and OmniPath to explore the pathway context of Q92542, identifying potential interactions and biological processes involved.
5. **Druggability assessment**: If validated, assess the druggability of Q92542 using databases like DGIdb and ChEMBL to explore potential therapeutic interventions.
These steps will provide a comprehensive framework for evaluating the relevance of Q92542 in HS and its potential as a therapeutic target.